Exelixis (EXEL) Q1 2026: CaboMedics TRX Volume Up 14% as ZANSA Franchise Build Accelerates
Exelixis delivered robust Q1 execution, with CaboMedics prescription volume outpacing the market and ZANSA pivotal programs expanding across major tumor types. The company is leveraging its commercial strength in renal cell carcinoma and neuroendocrine tumors while expediting launch readiness for ZANSA in colorectal cancer. Capital allocation remains balanced between R&D, buybacks, and pipeline expansion, positioning Exelixis for a potential franchise transition in the 2030s.
Summary
- CaboMedics Outpaces Market: Prescription growth and market share gains reinforce franchise durability.
- ZANSA Pipeline Momentum: Seven pivotal trials and new indications signal a multi-franchise oncology strategy.
- Capital Deployment Balances Growth and Returns: Buybacks and R&D investment reflect confidence in long-term value creation.
Business Overview
Exelixis is an oncology-focused biopharma developing and commercializing small molecule therapies for solid tumors. The company’s core revenue driver is the CaboMedics franchise, a tyrosine kinase inhibitor (TKI) primarily for renal cell carcinoma (RCC) and neuroendocrine tumors (NETs). Emerging pipeline assets, led by ZANSA (zanzalitinib), are positioned for future launches in colorectal, kidney, and other cancers, supported by a global partner network and internal R&D.
Performance Analysis
Exelixis posted strong top-line growth in Q1 2026, with the CaboMedics franchise sustaining leadership in its core markets. Prescription volumes for CaboMedics rose 14% year-over-year, outpacing the 7% growth of the overall oral TKI market basket and driving a three-point market share gain to 47%. The company’s U.S. Cabo franchise net product revenue increased 8% year-over-year, with global franchise revenue growing even faster through partner contributions.
Gross-to-net deductions increased to 30.2%, reflecting higher 340B volumes, Medicare Part D rebates, and copay assistance, but operating expenses were well-controlled, declining slightly on a sequential basis due to lower clinical trial costs. Cash generation remains robust, enabling aggressive share repurchases—$430.8 million in Q1—and the authorization of a new $750 million buyback program. Exelixis ended the quarter with $1.4 billion in cash and marketable securities, supporting both pipeline advancement and shareholder returns.
- Prescription Share Expansion: CaboMedics grew market share from 44% to 47% YoY, reinforcing its category leadership.
- Operating Leverage: Sequential decrease in operating expenses reflects disciplined cost management amid clinical trial spend variability.
- Capital Return: Substantial buybacks signal management’s conviction in undervaluation and future pipeline-driven growth.
Momentum in both commercial execution and pipeline progression positions Exelixis for a critical year of transition and potential inflection.
Executive Commentary
"ExoLexus is off to a strong start in 2026 with meaningful progress across our discovery, development, and commercial activities. Our strategy has a singular focus to build a multi-franchise business in solid tumor oncology focused on GU and GI histologies based on the depth of the cabozantinib business, potential breadth of the ZANSA opportunity, and the scope of our early-stage pipeline."
Mike Morrissey, President and Chief Executive Officer
"We are a financially strong company. We have significant cash flows. We're prioritizing our R&D spend on a constant basis so that we're understanding what projects are kind of sticking their heads up and saying, fund us...and from a share buyback perspective, we believe that ZANSA is a great opportunity and that, you know, that if that opportunity is not really being appreciated generally and we think we're undervalued, so we're going to continue to buy back shares."
Chris Center, Chief Financial Officer
Strategic Positioning
1. CaboMedics Franchise Optimization
CaboMedics, Exelixis’ leading TKI, continues to dominate in RCC and neuroendocrine tumors, with broad physician adoption and favorable perception versus competitors. Expansion of the GI sales team is designed to drive deeper community penetration and set the stage for future launches.
2. ZANSA as Next-Gen Oncology Platform
ZANSA (zanzalitinib) is positioned as the company’s next major franchise, with an NDA under review for third-line plus colorectal cancer and seven pivotal trials spanning colorectal, RCC, NETs, and other solid tumors. Early regulatory and KOL feedback is highly positive, and Exelixis is preparing for broad label expansion and multi-indication leadership through the 2030s.
3. Pipeline and Clinical Development Breadth
Exelixis is running one of the broadest development programs for an unapproved oncology drug, with multiple shots on goal in RCC (LightSpark 033, 034, Stellar 304), NETs (Stellar 311), and exploratory efforts in lung and prostate cancers. Early-stage assets and novel combinations, including bispecific IOs and ADCs, are being prioritized for rapid go/no-go decisions.
4. Capital Allocation Discipline
Management balances R&D investment, business development, and capital returns, with significant share repurchases and a readiness to pursue external innovation at the right price. Cash flow strength underpins both pipeline advancement and shareholder value initiatives.
5. Commercial Launch Readiness
Launch preparation for ZANSA in CRC is in full swing, leveraging the expanded GI sales force and market research indicating a $1.5 billion U.S. opportunity in third-line plus CRC. Experience with CaboMedics provides a strong foundation for rapid uptake upon approval.
Key Considerations
Exelixis’ Q1 underscores a pivotal period of franchise expansion, pipeline execution, and capital discipline. The company’s multi-pronged approach seeks to sustain CaboMedics while accelerating ZANSA’s market entry and clinical footprint.
Key Considerations:
- ZANSA Regulatory Milestones: The upcoming PDUFA decision and final NLM data from Stellar 303 will be critical for CRC franchise validation.
- Clinical Breadth as Risk Mitigation: Multiple pivotal trials across tumor types diversify development risk and expand addressable markets.
- GI Sales Force Expansion: Early investment in commercial infrastructure is designed to maximize near-term CaboMedics growth and enable a seamless ZANSA launch.
- Capital Allocation Flexibility: Strong cash position supports simultaneous investment in pipeline, business development, and aggressive share repurchases.
Risks
Exelixis faces execution risk in launching ZANSA across multiple indications, especially as regulatory outcomes and competitive dynamics in RCC and CRC evolve. Gross-to-net pressure from payer dynamics and higher rebates could weigh on future margins. Clinical trial complexity and the need for positive pivotal readouts remain central to sustaining long-term growth and justifying capital allocation priorities.
Forward Outlook
For Q2 2026, Exelixis guided to:
- Completion of the October 2025 $750 million share repurchase plan in May
- Progress toward Stellar 303 NLM data readout and continued enrollment in key ZANSA pivotal trials
For full-year 2026, management reiterated guidance:
- Continued CaboMedics revenue growth and tight operating expense control
Management emphasized readiness for ZANSA CRC launch, ongoing pivotal trial initiations, and disciplined capital allocation as primary drivers for the remainder of the year.
- PDUFA decision for ZANSA in CRC expected in December
- Multiple pivotal trial readouts and initiations slated for 2026
Takeaways
Exelixis is executing on a dual-franchise oncology strategy, leveraging CaboMedics’ market leadership while positioning ZANSA for multi-indication expansion. Commercial and R&D investments are tightly aligned, with capital returns reflecting management’s confidence in pipeline-driven value creation.
- Commercial Outperformance: CaboMedics continues to gain share and volume, providing a stable base for pipeline investment.
- Pipeline Diversification: ZANSA’s broad pivotal program and early-stage assets enhance both upside and risk mitigation.
- Watch for Regulatory and Clinical Catalysts: Key data readouts and the ZANSA CRC approval decision will shape near- and long-term trajectory.
Conclusion
Exelixis delivered a strong Q1 with commercial momentum and disciplined execution across its pipeline. The company’s dual-franchise strategy, robust capital allocation, and clinical breadth position it for a potential inflection as ZANSA approaches regulatory milestones and commercial launch.
Industry Read-Through
Exelixis’ approach highlights the increasing importance of franchise-building in oncology, with companies seeking to maximize existing assets while rapidly advancing next-generation molecules across multiple indications. The emphasis on early commercial infrastructure build-out and multiple pivotal trial “shots on goal” reflects a broader industry trend toward risk diversification and accelerated market entry. Gross-to-net pressures and payer dynamics remain a sector-wide concern, while the willingness to deploy significant capital toward share repurchases signals a belief in persistent undervaluation among pipeline-heavy biopharma peers. Other oncology developers should note the operational and strategic discipline required to transition from single-asset to multi-franchise portfolios in an increasingly competitive landscape.